1,721,104 research outputs found
Aortic valve sclerosis:new help from echocardiography in the assessment of cardiovascular risk
No full textTransradial approach for percutaneous closure of patent ductus arteriosus with the Amplatzer duct occluder II: a case report
No full text
Dual chamber pacing in hypertrophic cardiomyopathy: is there evidence for a real benefit?
No full text
Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients
No full textThere is little information on left ventricular (LV) hypertrophy (LVH)
development during antihypertensive treatment. We evaluate incident LVH in a
treated hypertensive cohort, the Campania Salute Network registry. We analyzed
prospectively 4290 hypertensives (aged 50.3±11.1 years, 40% women) with at least
1-year follow-up, without LVH at baseline. Incident LVH was defined as the first
detection of echocardiographic LV mass index ≥47 in women or ≥50 g/m2.7 in men.
During a median 48-month follow-up, 915 patients (21.3%) developed LVH. They were
older, more frequently women, and obese (P<0.0001), with initial higher fasting
glucose, diastolic and systolic blood pressure, LV mass index, lower heart rate
and glomerular filtration rate, longer hypertension history and follow-up, and
higher average systolic blood pressure during follow-up (all P<0.05), despite a
more frequent treatment with Ca++-channel blockers and diuretics (both P<0.02).
At multivariable Cox regression, incident LVH was independently associated with
older age, female sex, obesity, higher average systolic blood pressure during
follow-up, and initial greater LV mass index (all P<0.02). By categorizing
patients according to obesity and sex, obesity independently increased the risk
for incident LVH in both sexes (obese versus nonobese men: hazard ratio, 1.34;
confidence interval, 1.05-1.72; P=0.019; and obese versus nonobese women: hazard
ratio, 1.34; confidence interval, 1.08-1.66; P=0.007). Despite more aggressive
antihypertensive therapy, 21% of hypertensive patients develop clear-cut LVH.
After adjusting for confounders, risk of incident LVH is particular relevant
among women and is further increased by the presence of obesity.CLINICAL TRIAL
REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02211365
Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran
No full text: Vitamin K-dependent antagonists (VKAs) are the most commonly used oral anticoagulants. Non-VKA oral anticoagulants (NOACs), directly target factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, and edoxaban) have predictable pharmacological effects and relatively few drug and food interactions compared with VKA. Among NOACs, dabigatran has been extensively tested for stroke prevention in patients with non-valvular atrial fibrillation eligible for oral anticoagulation with VKA. Dabigatran is at least as effective as warfarin at preventing stroke with advantages of less serious bleeding except for gastrointestinal bleeding, which occurs more often than with warfarin. The findings of dabigatran use in randomized trials, post market registries and specific clinical settings are discussed in this article
- …
